Hemoliv

Hemoliv is an over‑the‑counter oral product whose sole active ingredient is diosmin, a phlebotonic compound. While the specific strength is not disclosed, the formulation is designed for systemic use in the European market. Diosmin belongs to the vascular‑protective drug class (ATC code C05CA03) and works by enhancing venous tone, reducing capillary permeability, and supporting lymphatic drainage. Hemoliv is marketed for conditions related to venous circulation.

Hemoliv is indicated for several common vascular disorders that affect the lower extremities and the anorectal region. Clinical use focuses on improving symptoms and quality of life.

- Chronic venous insufficiency, including leg heaviness, swelling, and aching. - Symptomatic relief of hemorrhoidal disease such as bleeding, itching, and discomfort. - Management of mild to moderate varicose veins and associated leg pain. - Adjunctive support after venous surgery or sclerotherapy to promote healing. - Prevention of capillary fragility in patients prone to bruising.

The safety profile of Hemoliv reflects the typical experience with oral diosmin preparations. Reported adverse events are generally mild, but rare serious reactions have been described.

Common: - Gastro‑intestinal discomfort such as nausea or abdominal cramps. - Headache or mild dizziness. - Transient skin flushing or warmth. - Loose stools or mild diarrhea. - Mild heartburn or acid reflux.

Serious: - Allergic reactions including rash, pruritus, or angio‑edema. - Severe abdominal pain suggestive of ulceration. - Hepatic enzyme elevation in isolated cases. - Thrombotic events (extremely rare) reported with high‑dose combinations. - Blood clotting abnormalities (e.g., thrombocytopenia) reported rarely. - High‑dose vitamin C supplements, which may alter diosmin absorption.

When considering Hemoliv, certain precautionary measures should be observed to minimize risk and ensure appropriate use.

- Not recommended for individuals with known hypersensitivity to diosmin or related flavonoids. - Caution in patients with active gastrointestinal ulcers or inflammatory bowel disease. - Use under medical supervision during pregnancy or breastfeeding, as safety data are limited. - Monitor liver function in patients with pre‑existing hepatic impairment. - Avoid prolonged use without periodic clinical review. - Consider dose adjustment in elderly patients due to potential altered metabolism.

Hemoliv may interact with other medications or supplements that affect vascular tone, coagulation, or metabolism.

Avoid: - Concurrent use with anticoagulants (e.g., warfarin, direct oral anticoagulants) that could increase bleeding risk. - Combination with other venotonic agents containing hesperidin or rutin without professional guidance. - High‑dose vitamin C supplements, which may alter diosmin absorption.

Use with caution: - Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may irritate the gastrointestinal tract. - Diuretics, as changes in fluid balance could modify symptom perception. - Herbal products such as ginkgo biloba or garlic that have antiplatelet activity. - Corticosteroids, because they can affect capillary permeability and mask efficacy.